The MarketWatch News Department was not involved in the creation of this content. FDA-approved for cheek augmentation and/or age-related midface contour deficiencies, in adults aged 22 years or older, ...

Revance announces today that RHA® Redensity is now available, following the completion of an early training and education program (PrevU), initiated in July 2022. RHA® Redensity is the latest ...

Today, we take a deeper look at Revance Therapeutics, Inc., a developer of aesthetic products that is seeing rapid revenue growth. The company has potential catalysts on the horizon but is bumping up ...

Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded on ...

NASHVILLE, Tenn., March 24, 2026 /PRNewswire/ -- Revance and Teoxane announce today that RHA ® Dynamic Volume, formerly RHA ® 4 Mepi, is now available. RHA ® Dynamic Volume is a product designed with ...

RHA® Collection revenue increased 42.6% year-over-year to $26.1 million in the third quarter. Strong RHA® Collection revenue growth was driven by new account growth, increased account productivity, ...

Through our focused execution and with the introduction of new innovation RHA Redensity, we increased adoption, enhanced account productivity, and are very pleased to report a 51% revenue increase ...